The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
23.04. MG at Proactive London."Martin Gouldstone, Oncimmune’s Chief Executive Officer, said: “As ageing-related diseases become more prevalent in society we believe that our ImmunoINSIGHTS technology can be instrumental in finding better diagnosis and treatment solutions for these diseases, while making clinical trials more efficient and productive. We are working closely with our partners in this area and I look forward to discussing the topic with world-leading experts later this month.”
"The company is already working with leading drug discovery companies on ageing-related research and has been approached by several global pharmaceutical companies about the use of its technology in this field."
Time will tell but I have observed this company for a while now and I guarantee that the upside potential for this is tremendous. The diagnostics market is poised to expand considerably over the coming years and with the diverse application of ONCimmune's service, I think deals will be closed. Many deals.
I also believe that the (Bio-) Pharma industry is awake and on the up again. Coming out of a prolonged period of under investment and bearish sentiment, there is a lot more activity on the M&A market. I can see a bull charging from the distance
In the most recent report from Feb 24, it was indicated that H1 FY24 results should be made public via a trade update in May. I assume that the shares will start to get bought up because it is a phenomenal entry price for a business that will have their first 'clean' report post sale of non-core assets. This report will show an expected high increase in revenue and possibly reveal a rich and growing pipeline. At this point the strategy I'd defined, the resources are all hired, the overheads are gone and the margins are wide. On top of that there is a solid baseline revenue from existing contracts incl. Freenome and other MSA and ongoing projects. Many more to come. I believe we are at the 'tipping point' right now.
I hope others agree. Curious to read other opinions. But I cannot see the SP going back down from here, quite the opposite
I wish i had some spare change right now... ONC taking a big hit knocking off 20%. At these levels a definete buy to get the average down.
Like you said Dr. This is a long game but i firmly believe that the latest report will have been the worst summing up a year of change and metamorphosis.
I think right now is when the cocoon cracks...
I have not. I think the company has been in this spot here 2 years ago when the Sales strategy and structure was laid out by former CEO. Company needs to prove that debt to equity ratio is solid and not spiral out of control. I think there should be a check around that given reduced overheads from asset sale.
The other component is proof that there is sustainable and predictable growth in the stock. I hope 150% is the start to a consistent acceleration based on repeat customer contracts MSAs and longer term commitments as from Freenome.
Sad to say it may take another couple of reports for this to recover but based on the fugures (unmuddied by sale of Oncimmune Plc), right now i think is a smashing SP.....if you believe in thw longer term prospects of the business. I do
Vox Market's Paul Hill interviews Martin Gouldstone CEO ONC
https://youtu.be/YxLVTHyDw3Q?si=08QtPox2ApkYmz_5
Hi all. I am reading a highly encouraging report with exciting prospects, growth and marging expansion.
Revenue in FY 2024 expected to be approximately £3m, compared with FY 2023 revenue from continuing operations of £1.2m, a growth rate of 150%. Coming up to the end of H1 FY 2024, work to achieve approximately 75% of the forecast FY 2024 revenue has been secured, with the majority of samples received or expected imminently allowing lab work to begin and revenue to be recognised in due course.
Sorry to hear that mc. You are not the only one with a gaping loss %.... many have already jumped ship and some have not yet cut the cord.
Lots of frustration here with this SP. Freenome doing very well esp since acquisition of non core ONC business. As for ONC now i just could not imagine this business failing to capitalise on their pole position and the largely untapped market. With ONCs margins and new structure leadership and commercial approach etc i would question whether every little thing in this world if this was not the bottom of where this SP sits.
Years ago they made 170k revenue and shares traded at close to 1GBP.
This could have been due to low i terest rates and the pote tially great growth prospects. I expect strong growth guidance from leadership and over time i terest rates will go down too. OnC is already making tons more revenue than 170k.
To all here. Am I naive in wanting to hold for another fiscal at the minimun to seethe pendulum finally swing the other way?
I see this stock being traded down coincidentally in line with wider market movements.
#PCE reading
# GDP data
Is there another reason we are seeing 9%drop today. Or are we just bracing for the number we are about to be exposed to for FY23.
I want to agree with you on the confidence in new leadership and strategy as well as Presentation well received part. I had topped up as well after watching the interview. Addressable market is enormous and as mentioned hard to predict exact size because the boundaries of the application of ONC ImmunoInsights are ever expanding. Perhaps interest rate developments just coincide with the news coming from ONC. Maybe the combination is doing the trick.....in any case we have a highly motovated leadership that knows Big Pharma and Biotech and have been hired for their ability to scale ONC from single digit mio revenue to multi-digit revenue company.
Commercial focus
Investors in mind
Bleeding edge of Innovation (Luminex and AI....)
Leader in industry
Hardly any comparable comüetition
MSAs with Big Pharma companies
Established Sales Team
Time to crush it!
(Probably another 3-5 year hold..... then i may consider retirement....please!!!)
Nice pop in the SP. Again could be due to the news around interest rates.
My take is that as inflation goes down and Central banks start mulling the decrease in interest rates we will see a natural lift in the market. For ONC specifocally the coming Report will be interesting as there should be a good foundation of revenue stemming from the following 3 partnerships alone: Biodesix, Freenome and Siemens Healthineers, not to speak of all other business we have not been exposed to as much.
I have a feeling that similar to how fast the SP crashed, we may see it go back up again.
Super excited about the prospects.
Great find. The one day i didnt scan the market for news. ^^ have been waiting for this interview for a bit. And absolutely confident that we will see this business realise revenue from all the contracta they have landed to date and new ones they are landing. I am holding tight man!